LB Pharmaceuticals Inc Common Stock (LBRX) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
LB Pharmaceuticals Inc Common Stock (LBRX) Earnings Overview
As of June 30, 2026, LB Pharmaceuticals Inc Common Stock (LBRX) reported trailing twelve-month net income of -$39M, reflecting +94.4% year-over-year growth. The company earned $-1.39 per diluted share over the past four quarters.
Looking at the long-term picture, LBRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2023.
LB Pharmaceuticals Inc Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), ATHA (-$129M net income), INVA ($504M net income, 63.8% margin), LBRX has comparable earnings metrics. Compare LBRX vs SAVA →
LBRX Earnings vs Peers
Earnings metrics vs comparable public companies
LBRX Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$25M | +60.1% | -$30M | $-1.00 | - | - |
| 2024 | -$63M | -905.6% | -$65M | $-17.83 | - | - |
| 2023 | -$6M | +56.3% | -$11M | $-1.77 | - | - |
| 2022 | -$14M | - | -$3M | $-4.05 | - | - |
Download Data
Export LBRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LBRX — Frequently Asked Questions
Quick answers to the most common questions about buying LBRX stock.
What is LBRX earnings per share (EPS)?
LBRX trailing twelve-month (TTM) diluted EPS is $-1.39, reflecting +94.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is LB Pharmaceuticals Inc Common Stock's net income?
LB Pharmaceuticals Inc Common Stock (LBRX) trailing twelve-month net income is $-39M as of 2025. Earnings grew +94.4% year-over-year.
Is LBRX profitable?
LBRX is not currently profitable on a TTM basis, reporting a net loss of $-39M. Net margin is N/A. Investors should monitor for a return to profitability.
What is LBRX's earnings growth rate?
LBRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are LBRX's profit margins?
LB Pharmaceuticals Inc Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -24.4%.
Is LBRX growing earnings?
Yes, LBRX earnings are accelerating — EPS growth of +94.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-39M. Earnings momentum is strengthening.
What was LBRX's best earnings year?
LB Pharmaceuticals Inc Common Stock's highest annual net income on record is $-6M, achieved in fiscal year 2023. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were LBRX's earnings last quarter?
LBRX's most recent reported quarter was Q1 2026. Net income was $-19M with diluted EPS of $-0.67. For a full breakdown of all quarters, see the quarterly earnings table on this page.